Trials / Completed
CompletedNCT05713292
Pirfenidone in Adult Hospitalized Patients With COVID-19
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pirfenidone in Adult Hospitalized Patients With COVID-19.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Capital Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This center intends to conduct a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirfenidone Oral Product | Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months |
| DRUG | Pirfenidone placebo | Pirfenidone placebo |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2023-03-04
- Completion
- 2023-03-30
- First posted
- 2023-02-06
- Last updated
- 2024-07-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05713292. Inclusion in this directory is not an endorsement.